Details for Patent: 10,065,958
✉ Email this page to a colleague
Which drugs does patent 10,065,958 protect, and when does it expire?
Patent 10,065,958 protects VEKLURY and is included in one NDA.
Protection for VEKLURY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-five patent family members in twenty-nine countries.
Drugs Protected by US Patent 10,065,958
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | VEKLURY | remdesivir | POWDER;INTRAVENOUS | 214787-001 | Oct 22, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Gilead Sciences Inc | VEKLURY | remdesivir | SOLUTION;INTRAVENOUS | 214787-002 | Oct 22, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,065,958
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
African Regional IP Organization (ARIPO) | 3269 | ⤷ Try a Trial | |||
Australia | 2011280910 | ⤷ Try a Trial | |||
Australia | 2015238851 | ⤷ Try a Trial | |||
Australia | 2017201230 | ⤷ Try a Trial | |||
Australia | 2019208167 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |